BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...attacks in patients with hereditary angioedema (HAE) Submit NDA 4Q19 Biofrontera AG (NASDAQ:BFRA; Xetra:B8F) Ameluz aminolevulinic acid...
BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...Topoisomerase I Hongjiang Li, Staff Writer Evomela (Brand), melphalan (Generic), IV Captisol-enabled Melphalan (Informal), Evomela (Other) Gliolan, aminolevulinic acid Imlygic...
BioCentury | Mar 22, 2019
Clinical News

Biofrontera planning applications to expand Ameluz indication

...months after the last treatment (86% vs. 33%, p<0.0001). The therapy comprises nanoemulsion BF-200 with 5-aminolevulinic acid...
...actinic keratoses on the face and scalp. Hongjiang Li, Staff Writer Ameluz (Brand), BF-200 ALA (Compound #), aminolevulinic acid...
BioCentury | Mar 6, 2019
Clinical News

Alnylam's rare liver disease RNAi meets in Phase III

...on drug." Alnylam said givosiran also met several secondary endpoints in ENVISION, including improving urinary aminolevulinic acid...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Endocrine/Metabolic; neurology

...and rabbit models of AIP, LPN-encapsulated HMBS mRNA decreased urine levels of the porphyrin precursors 5-aminolevulinic acid...
BioCentury | Sep 28, 2018
Clinical News

Alnylam to seek accelerated approval for RNAi therapy in rare liver disease

...to treat acute hepatic porphyria after interim data showed that the compound significantly reduced urinary aminolevulinic acid...
...hospitalization, urgent healthcare visit or hemin administration at home over the six-month treatment period; urinary aminolevulinic acid...
BioCentury | Sep 27, 2018
Clinical News

Alnylam to seek accelerated approval for RNAi therapy in rare liver disease

...to treat acute hepatic porphyria after interim data showed that the compound significantly reduced urinary aminolevulinic acid...
BioCentury | May 30, 2018
Distillery Therapeutics

Neurology

...were higher than in samples from normal mice. In a mouse model of ATR-X, Gliolan aminolevulinic acid...
...in humanized models of ATR-X. Medac GmbH and Specialised Therapeutics Australia Pty. Ltd. market Gliolan aminolevulinic acid...
BioCentury | Jun 1, 2017
Distillery Therapeutics

Infectious disease

...INDICATION: Gram-negative bacterial infection Cell culture studies suggest combining tellurite anion and 5-aminolevulinic acid (ALA) could help...
...models of Gram-negative bacterial infection. Medac GmbH and Specialised Therapeutics Australia Pty. Ltd. market Gliolan aminolevulinic acid...
BioCentury | Dec 30, 2016
Clinical News

Ameluz regulatory update

...EMA’s CHMP recommended approval of an expanded label for Biofrontera’s Ameluz aminolevulinic acid to include treatment of...
...that has cancer-associated genetic or epigenetic alterations. The photodynamic therapy (PDT) comprises nanoemulsion BF-200 with 5-aminolevulinic acid...
...the BF-RhodoLED lamp. Biofrontera AG (Xetra:B8F), Leverkusen, Germany Product: Ameluz aminolevulinic acid (BF-200 ALA) Business: Cancer Meghan Sullivan 5-aminolevulinic acid Ameluz BF-200...
Items per page:
1 - 10 of 165